Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for NATALIZUMAB
- Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
- A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
- AttackMS - Treatment of People With Inflammatory Demyelination Suggestive of MS, or Definite MS, at First Presentation
- A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
- Natalizumab and Chronic Inflammation
- Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis
- Cladribine Tablets After Treatment With Natalizumab (CLADRINA)
- Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis
- A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab
- Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma
- A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV N
- Towards Personalized Dosing of Natalizumab in Multiple Sclerosis
- Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy
- Autologous Stem Cell Transplant for Crohn's Disease
- Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis
- Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
- Inflammatory Response In Schizophrenia
- Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis
- Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
- Methylprednisolone During the Switch Between Natalizumab and Fingolimod
- Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
- Clinical Disease Activity With Long Term Natalizumab Treatment
- Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study
- Natalizumab in Inclusion Body Myositis (IBM)
- Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab
- Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
- Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya
- Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies
- Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD
- Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)
- Natalizumab Subcutaneous Immunogenicity and Safety Study
- Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri
- Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
- Sub-Study: Analysis of JCV Antibody Index in MS Patients Treated With Teriflunomide - SWITCH-JCV
- Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
- Alternative Treatment Paradigm for Natalizumab Trial
- Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
- NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness
- Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
- The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
- Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
- A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
- Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
- Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)
- Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)
- Natalizumab De-escalation With Interferon Beta-1b
- Natalizumab Treatment of Progressive Multiple Sclerosis
- Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis
- Treatment Interruption of Natalizumab
- JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
- JC-Virus (JCV) Antibody Program
- Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
- A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
- Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment
- Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study
- A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
- A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201
- Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy
- A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a
- A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State
- CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
- Study of Natalizumab in Relapsed/Refractory Multiple Myeloma
- Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
- A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone
- Tysabri Observational Program
- A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
- Natalizumab (Tysabri) Re-Initiation of Dosing
- Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease
- Open-Label Natalizumab Safety Extension Study
- Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
- Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
- Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate
- A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease
- Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease
- Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease
- Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
- Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
- Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
- Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
Clinical trials list
click for details